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Background:  Angiotensin receptor blockers (ARB’s) have been hypothesized to slow the progression of aortic root dilatation in Marfan’s 
syndrome (MFS) by virtue of decreasing transforming growth factor beta (TGF-B), the critical mediator in pathogenesis. We pooled the 
existing data from the prospective studies to determine if the relationship is significant.
methods:  PubMed was searched from 1990 till present to identify prospective studies of patients with MFS in which ARBs are used 
as intervention. Further inclusion criteria included a follow up of at least six months and the presence of a control group. Random 
effects model using standardized mean difference (SMD) was created to pool the aggregate data and I2 testing was done to ascertain 
heterogeneity.
results:  A total of 122 titles were screened after which 20 abstracts were considered. Out of the 5 studies identified, 2 were excluded 
because of the concomitant use of other interventions. Pooled overall estimates (3 studies, 94 patients) suggest that the use of ARB’s 
significantly slows the progression of aortic root dilatation SMD= -1.86(95% CI=-0.24 to -3.84). There was significant heterogeneity (93%) 
among the included studies.
Conclusion:  Use of ARB’s in MFS is associated with a significant decrease in the progression of aortic root dilatation. The results are 
limited by the small number of studies, statistical heterogeneity, limited duration of follow up and lack of hard clinical end points. Further 
studies are needed to address these limitations.
 
